Why the study?
Patients with hospital-acquired COVID-19 readmitted within 60 days face worse prognosis and mortality, prompting an evaluation of early readmission rates and the role of remdesivir treatment.
Does remdesivir treatment reduce early readmission in patients with hospital-acquired COVID-19?
Does remdesivir treatment reduce early readmission in patients with hospital-acquired COVID-19?
Remdesivir treatment during the initial hospitalization for hospital-acquired COVID-19 significantly reduces the odds of early readmission.
Remdesivir may lower readmission risk in hospital-acquired COVID-19; hypothesis-generating from Level 3 data.
BACKGROUND: The patients affected by hospital-acquired coronavirus disease 2019 (HA-COVID-19) who were readmitted in hospital within 60 days had worse prognosis and mortality. In this study the aim was the assessment of early readmission rate in HA-COVID-19 and the role of remdesivir treatment. MATERIALS AND METHODS: This observational retrospective study included patients with HA-COVID-19 hospitalized in different wards between Jan 2021 and Mar 2022. Early readmission rate was determined. A multivariate logistic regression was made to determine the predictive factors for re-hospitalization. RESULTS: =0.001). CONCLUSION: Readmission cumulative rate was about one tenth with higher mortality. The remdesivir use in the first hospitalization leads to significant reduction in the odds of readmission.
No takes yet. Share an insight, caveat, or question.
Boglione et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: